breast cancer
Conditions
Interventions
4 cycles of FEC followed by 4 cycles of nab-paclitaxel FEC Epi-ADM 90 mg/m2 and CPA 600 mg/m2 iv,day 1 every 3 weeks Nab-paclitaxel nab-paclitaxel: 260mg/m2, iv, day 1 every 3 weeks
Sponsors
Toho University Omori Medical Center
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1.Histologically confirmed Breast cancer 2. Clinical stage2-4 3. Expected to radical cure by operation and neoadjuvant chemotherapy 4. Has measurable region 5. Age >=20 6.No prior surgery, radiation, chemotherapy and endcrinethrapy 7.Required baseline laboratory parameters (within 14 days before registration): Hb more than 9.0g/dl WBC >= 3500 /mm3 and <= 12,000 /mm3 Neu >= 2000 / mm3 Plt >= 100,000/mm3 T-Bil <= 2 times ULM AST<= ULNx2 ALT<= ULNx2 Creatinin <=1.5 mg/dL Ccr <=50 ml/min 8.Performance status 0-1 9. Oral administration is available 10.Written IC
Exclusion criteria
Exclusion criteria: 1.Inflammatory and bilateral breast cancer 2.Active another cancer 3.History of hypersensitivity reaction 4. Other severe complications, such as pulmonary emphysema or pulmonary fibrosis, uncontrollable diabetes, heart failure, renal insufficiency, liver failure 5. Contraindication to the study drugs 6. Has active infection or fever which suspected of infection 7.During administration of flucytosine, phenytoin, warfarin potassium 8.Physician judged improper to entry this trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pathological complete response rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Pathological response rate,Rasponse rate,Safty | — |
Countries
Japan
Contacts
Public ContactSyunsuke Magoshi
Toho University Omori Medical Center Breast and Endocrine Surgery
Outcome results
None listed